Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes

• Status: Completed
• Trial end date: 2018-08-16
• Target enrollment: 0
• Participant gender: All

Summary

In the proposed study, hydroalcoholic Fenugreek seed extract will used add-on to the existing therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be evaluated using standard methodology.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar
• Collaborator: Chemical Resources
• Treatments: Fenugreek seed meal; Hypoglycemic Agents; Metformin

Criteria

Inclusion Criteria:

• Patients suffering from Type-2 Diabetes of less than 10 years duration

• Patients with HbA1c >7.0%

• Patients with fasting plasma glucose not exceeding 180 mg/dL

• Patients with Negative Urine sugar

• Patients who are on oral hypoglycaemic agents containing either Metformin or Sulfonylurea or both

• There should not be any change their in anti-diabetic treatment for at least one month

Exclusion Criteria:

• Patients with diabetes other than type-2 diabetes mellitus

• Patients with evidence of renal disease (S. Creatinine > 1.5mg/dL)

• Patients with evidence of liver disease (AST/ALT >3 times of normal

• Pregnant and lactating mothers and women intending pregnancy

• Patients who participated in any other clinical trial within the last 30 days

• Patients with history of any hemoglobinopathy

• History of intolerance or hypersensitivity to Fenugreek